The implications of oxidative stress and antioxidant therapies in Inflammatory Bowel Disease: Clinical aspects and animal models

Saudi Journal of Gastroenterology

Volumn 22, Issue 1, 2016, Pages 3-17

  Balmus, Ioana ^a   Ciobica, Alin ^a,b   Trifan, Anca ^c   Stanciu, Carol ^b  

^a ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

^b ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

^c GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Animal models; antioxidants; Crohn's disease; lipid peroxidation; reactive oxygen species; ulcerative colitis

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; EPIDERMAL GROWTH FACTOR; GLUTATHIONE DISULFIDE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; KYNURENINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA1; TRYPTOPHAN; REACTIVE NITROGEN SPECIES;

ADAPTIVE IMMUNITY; CROHN DISEASE; DISEASE ASSOCIATION; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INFLAMMATORY CELL; INNATE IMMUNITY; LIPID PEROXIDATION; MACROPHAGE; MOLECULAR PATHOLOGY; NEUTROPHIL; NITROSATIVE STRESS; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHAGOCYTE; PROTEIN EXPRESSION; REVIEW; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; INFLAMMATORY BOWEL DISEASES; METABOLISM;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; LIPID PEROXIDATION; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84955458118     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.173753     Document Type: Review

References (149)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: Cause and immunobiology. Lancet 2007;369:1627-40.
2. Borody TJ, Campbell J, Torres M, Nowak A, Leis S. Reversal of idiopathic thrombocytopenic purpura [ITP] with fecal microbiota transplantation [FMT]. Am J Gastroenterol 2011;106:S352.
3. Wendland BE, Aghdassi E, Tam C, Carrier J, Steinhart AH, Wolman SL, et al. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr 2001;74:259-64.
4. Halliwell B. Antioxidants and human disease: A general introduction. Nut Rev 1997;55:S44-52.
5. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: An overview. Methods Enzymol 1990;186:1-85.
6. Rice-Evans C, Burdon R. Free radical-lipid interactions and their pathological consequences. Prog Lipid Res 1993;32:71-110.
7. Frei B, Stocker R, Ames BN. Antioxidant defenses and lipid peroxidation in human blood plasma. Proc Natl Acad Sci USA 1998;85:9748-752.
8. Thomas SR, Davies MJ, Stocker R. Oxidation and antioxidation of human low-density lipoprotein and plasma exposed to 3-morpholinosydnonimine and reagent peroxynitrite. Chem Res Toxicol 1998;11:484-94.
9. Knutson MD, Walter PB, Ames BN, Viteri FE. Both iron deficiency and daily iron supplements increase lipid peroxidation in rats. J Nutr 2000;130:621-8.
10. Oldenburg B, van Berge Henegouwen GB, Rennick D, van Asbeck BS, Koningsberger JC. Iron supplementation affects the production of pro-inflammatory cytokines in IL-10 deficient mice. Eur J Clin Invest 2000;30:505-10.
11. Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther 2001;15:1989-99.
12. Carrier J, Aghdassi E, Cullen J, Allard JP. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr 2002;132:3146-50.
13. Barollo M, D'Inca M, Scarpa M, Medici V, Cardin R, Bortolami R, et al. Effects of iron manipulation on trace elements level in a model of colitis in rats. World J Gastroenterol 2005;11:4396-9.
14. Erichsen K, Milde AM, Arslan G, Helgeland L, Gudbrandsen OA, Ulvik RJ, et al. Low-dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis. Inflamm Bowel Dis 2005;11:744-8.
15. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985;312:159-63.
16. Canãs PE. The role of xanthine oxidase and the effects of antioxidants in ischemia reperfusion cell injury. Acta Physiol Pharmacol Ther Latinoam 1999;49:13-20.
17. Krinsky NI. Mechanism of action of biological antioxidants. Proc Soc Exp Biol Med 1992;200:248-54.
18. Machlin LJ, Bendich A. Free radical tissue damage: Protective role of antioxidant nutrients. FASEB J 1987;1:441-5.
19. Fang YZ, Yang S, Wu G. Free radicals, antioxidants, and nutrition. Nutrition 2002;18:872-9.
20. Floyd RA. Role of oxygen free radicals in carcinogenesis and brain ischemia. FASEB J 1990;4:2587-97.
21. Alzoghaibi MA. Concepts of oxidative stress and antioxidant defense in Crohn's disease. World J Gastroenterol 2013;19:6540-7.
22. Fernandez-Banares F, Abad-Lacruz A, Xiol X, Gine JJ, Dolz C, Cabre E, et al. Vitamin status in patients with inflammatory bowel disease. Am J Gastroenterol 1989;84:744-8.
23. Wetscher GJ, Perdikis G, Kretchmar DH, Stinson RG, Bagchi D, Redmond EJ, et al. Esophagitis in Sprague-Dawley rats is mediated by free radicals. Dig Dis Sci 1995;40:1297-305.
24. Olliver JR, Hardie LJ, Gong Y, Dexter S, Chalmers D, Harris KM, et al. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2005;14:620-5.
25. Oh TY, Lee JS, Ahn BO, Cho H, Kim WB, Kim YB, et al. Oxidative damages are critical in pathogenesis of reflux esophagitis: Implication of antioxidants in its treatment. Free Radic Biol Med 2005;30:905-15.
26. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127-31.
27. Mai UE, Perez-Perez GI, Allen JB, Wahl SM, Blaser MJ, Smith PD. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in gastric mucosa. J Exp Med 1992;175:517-25.
28. An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 1993;341:1359-62.
29. Davies GR, Simmonds NJ, Stevens TR, Sheaff MT, Banatvala N, Laurenson IF, et al. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 1994;35:179-85.
30. Farinati F, Cardin R, Libera GD, Rugge M, Herszènyi L, Di Mario F, et al. Determinants for the development of chronic atrophic gastritis and intestinal metaplasia in the stomach. Eur J Cancer Prev 1995;4:181-6.
31. Seril DN, Liao J, Yang G, Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: Studies in humans and animal models. Carcinogenesis 2003;24:353-62.
32. D'Incà R, Cardin R, Benazzato L, Angrima I, Martines D, Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis 2004;10:23-7.
33. Damiani CR, Benetton CA, Stoffel C, Bardini KC, Cardoso VH, Di Giunta G, et al. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol 2007;22:1846-51.
34. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
35. Omatsu T, Naito Y, Handa O, Mizushima K, Hayashi N, Qin Y, et al. Reactive oxygen species-quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. J Gastroenterol 2005;45:692-702.
36. Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J 2006;82:186-91.
37. Chattopadhyay I, Bandyopadhyay U, Biswas B, Maity P, Banerjee RK. Indomethacin inactivates gastric peroxidase to induce reactive-oxygen-mediated gastric mucosal injury and curcumin protects it by preventing peroxidase inactivation and scavenging reactive oxygen. Free Radic Biol Med 2006;40:1397-408.
38. Lim YJ, Lee JS, Ku YS, Hahm KB. Rescue strategies against non-steroidal anti-inflammatory drug-induced gastroduodenal damage. J Gastroenterol Hepatol 2009;24:1169-78.
39. Wetscher GJ, Hinder RA, Bagchi D, Hinder PR, Bagchi M, Perdikis G, et al. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am J Surg 1997;170:552-7.
40. Erbil Y, Türkoglu U, Barbaros U, Balik E, Olgac V, Kaya H, et al. Oxidative damage in an experimentally induced gastric and gastroduodenal reflux model. Surg Innov 2005;12:219-25.
41. Dvorak K, Payne CM, Chavarria M, Ramsey L, Dvorakova B, Bernstein H, et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: Relevance to the pathogenesis of Barrett's oesophagus. Gut 2007;56:763-71.
42. Boughton-Smith NK, Evans SM, Hawkey CJ, Cole AT, Balsitis M, Whittle BJ, et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993;342:338-40.
43. Kuroki F, Iida M, Tominaga M, Matsumoto T, Hirakawa K, Sugiyama S, et al. Multiple vitamin status in Crohn's disease. Correlation with disease activity. Dig Dis Sci 1993;38:1614-8.
44. Kuroki F, Iida M, Tominaga M, Matsumoto T, Hirakawa K, Fujishima M. Is vitamin E depleted in Crohn's disease at initial diagnosis? Dig Dis 1994;12:248-54.
45. Bousvaros A, Zurakowski D, Duggan C, Law T, Rifai N, Goldberg NE, et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: Effect of disease activity. J Pediatr Gastroenterol Nutr 1998;26:129-35.
46. Schoon EJ, Müller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrügger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: Another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001;48:473-7.
47. Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 2004;53:1129-36.
48. Tajika M, Matsuura A, Nakamura T, Suzuki T, Sawaki A, Kato T, et al. Risk factors for vitamin D deficiency in patients with Crohn's disease. J Gastroenterol 2004;39:527-33.
49. Reimund JM, Arondel Y, Escalin G, Finck G, Baumann R, Duclos B. Immune activation and nutritional status in adult Crohn's disease patients. Dig Liver Dis 2005;37:424-31.
50. Ghishan FK, Kiela PR. Advances in the understanding of mineral and bone metabolism in inflammatory bowel diseases. Am J Physiol Gastrointest Liver Physiol 2005;300:G191-201.
51. Was̈ko-Czopnik D, Paradowski L. The influence of deficiencies of essential trace elements and vitamins on the course of Crohn's disease. Adv Clin Exp Med 2012;21:5-11.
52. Reimund JM, Allison AC, Muller CD, Dumont S, Kenney JS, Baumann R, et al. Antioxidants inhibit the in vitro production of inflammatory cytokines in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1998;28:145-50.
53. Alzoghaibi MA, Walsh SW, Willey A, Fowler AA 3 rd, Graham MF. Linoleic acid, but not oleic acid, upregulates the production of interleukin-8 by human intestinal smooth muscle cells isolated from patients with Crohn's disease. Clin Nutr 2003;22:529-35.
54. Buffinton GD, Doe WF. Altered ascorbic acid status in the mucosa from inflammatory bowel disease patients. Free Radic Res 1995;22:131-43.
55. Geerling BJ, Badart-Smook A, Stockbrügger RW, Brummer RJ. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr 1998;67:919-26.
56. Rath HC, Caesar I, Roth M, Schölmerich J. Nutritional deficiencies and complications in chronic inflammatory bowel diseases. Med Klin (Munich) 1998;93:6-10.
57. Geerling BJ, Houwelingen AC, Badart-Smook A, Stockbrügger RW, Brummer RJ. The relation between antioxidant status and alterations in fatty acid profile in patients with Crohn disease and controls. Scand J Gastroenterol 1999;34:1108-16.
58. Filippi J, Al-Jaouni R, Wiroth JB, Hébuterne X, Schneider SM. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm Bowel Dis 2006;12:185-91.
59. Hengstermann S, Valentini L, Schaper L, Buning C, Koernicke T, Maritschnegg M, et al. Altered status of antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. Clin Nutr 2008;27:571-8.
60. Valentini L, Schaper L, Buning C, Hengstermann S, Koernicke T, Tillinger W, et al. Malnutrition and impaired muscle strength in patients with Crohn's disease and ulcerative colitis in remission. Nutrition 2008;24:694-702.
61. Farrugia G, Balzan R. The Proapoptotic Effect of Traditional and Novel Nonsteroidal Anti-Inflammatory Drugs in Mammalian and Yeast Cells. Oxid Med Cell Longev 2013: 504230.
62. Colombel JF, Loftus EV Jr, Tremain WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
63. Ingraham LM, Coates TD, Allen JM, Higgins CP, Baehner RL, Boxer LA. Metabolic, membrane and functional responses of human polymorphonuclear leukocytes to platelet-activating factor. Blood 1982;59:1259-66.
64. Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984;86:453-60.
65. Kitahora T, Suzuki K, Asakura H, Yoshida T, Suematsu M, Watanabe M, et al. Active oxygen species generated by monocytes and polymorphonuclear leukocytes in Crohn's disease. Dig Dis Sci 1988;33:951-5.
66. Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, et al. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 1998;42:180-7.
67. Oudkerk Pool M, Bouma G, Visser JJ, Kolkman JJ, Tran DD, Meuwissen SG, et al. Serum nitrate levels in ulcerative colitis and Crohn's disease. Scand J Gastroenterol 1995;30:784-8.
68. Tauber AI, Babior BM. Neutrophil oxygen reduction: The enzymes and the products. Adv Free Radical Biol Med 1985;1:265-307.
69. Winterbourn CC. Myeloperoxidase as an effective inhibitor of hydroxyl radical production. Implications for the oxidative reactions of neutrophils. J Clin Invest 1986;78:545-50.
70. Britigan BE, Coffman TJ, Buettner GR. Spin trapping evidence for the lack of significant hydroxyl radical production during the respiration burst of human phagocytes using a spin adduct resistant to superoxide-mediate destruction. J Biol Chem 1990;265:2650-6.
71. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365-76.
72. Thomas EL, Grisham MB, Jefferson MM. Myeloperoxidase-dependent effect of amines on functions of isolated neutrophils. J Clin Invest 1983;72:441-54.
73. Grisham MB. Effect of 5-aminosalicylic acid on ferrous sulfate-mediated damage to deoxyribose. Biochem Pharmacol 1990;39:2060-3.
74. Genser D, Kang MH, Vogelsang H, Elmadfa I. Status of lipidsoluble antioxidants and TRAP in patients with Crohn's disease and healthy controls. Eur J Clin Nutr 1999;53:675-9.
75. Erichsen K, Hausken T, Ulvik RJ, Svardal A, Berstad A, Berge RK. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn's disease. Scand J Gastroenterol 2003;38:543-8.
76. Forrest CM, Gould SR, Darlington LG, Stone TW. Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease. Adv Exp Med Biol 2003;527:395-400.
77. Rezaie A, Khalaj S, Shabihkhani M, Nikfar S, Zamani M et al. Study on the Correlations among Disease Activity Index and Salivary Transforming Growth Factor-β1 and Nitric Oxide in Ulcerative Colitis Patients. An NY Acad Sci 2007;1095:305-14.
78. Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci 2004;49:1433-7.
79. Holmes EW, Yong SL, Eiznhamer D, Keshavarzian A. Glutathione content of colonic mucosa: Evidence for oxidative damage in active ulcerative colitis. Dig Dis Sci 1998;43:1088-95.
80. Rezaie A, Ghorbani F, Eshghtork A, Zamani MJ, Dehghan G, Taghavi B, et al. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta1 in relation to disease activity in Crohn's disease patients. Ann N Y Acad Sci 2006;1091:110-22.
81. Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: Lessons learned from animal models and human genetics. Front Immunol 2013;4:280.
82. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014;20:6-21.
83. Zhang YZ, Li YY. Inflammatory bowel disease: Pathogenesis. World J Gastroenterol 2014;20:91-9.
84. Siegmund B, Zeitz M. Innate and adaptive immunity in inflammatory bowel disease. World J Gastroenterol 2011;17:3178-83.
85. Beisner J, Stange EF, Wehkamp J. Innate antimicrobial immunity in inflammatory bowel diseases. Expert Rev Clin Immunol 2010;6:809-18.
86. McGuckin MA, Eri R, Simms LA, Florin TH, Radford-Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis 2009;15:100-13.
87. Monteleone I, Vavassori P, Biancone L, Monteleone G, Pallone F. Immunoregulation in the gut: Success and failures in human disease. Gut 2003;50(Suppl 3):360-4.
88. Pedersen J, Coskun M, Soendergaard C, Salem M, Nielsen OH. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol 2014;20:64-77.
89. Coskun M, Olsen J, Seidelin JB, Nielsen OH. MAP kinases in inflammatory bowel disease. Clin Chim Acta 2011;412:513-20.
90. Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res 2013;76:1-8.
91. Bouzid D, Gargouri B, Mansour RB, Amouri A, Tahri N, Lassoued S, et al. Oxidative stress markers in intestinal mucosa of Tunisian inflammatory bowel disease patients. Saudi J Gastroenterol 2013;19:131-5.
92. Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 1996;41:2078-86.
93. Chiarpotto E, Scavazza A, Leonarduzzi G, Camandola S, Biasi F, Teggia PM, et al. Oxidative damage and transforming growth factor beta 1 expression in pretumoral and tumoral lesions of human intestine. Free Radic Biol Med 1996;22:889-94.
94. Jahanshahi G, Motavasel V, Rezaie A, Hashtroudi AA, Daryani NE, Abdollahi M. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig Dis Sci 2004;49:1752-7.
95. Krzystek-Korpacka M, Neubauer K, Matusiewicz M. Platelet-derived growth factor-BB reflects clinical, inflammatory and angiogenic disease activity and oxidative stress in inflammatory bowel disease. Clin Biochem 2009;42:1602-9.
96. Pelli MA, Trovarelli G, Capodicasa E, De Medio GE, Bassotti G. Breath alkanes determination in ulcerative colitis and Crohn's disease. Dis Colon Rectum 1999;42:71-6.
97. Koch TR, Yuan LX, Stryker SJ, Ratliff P, Telford GL, Opara EC. Total antioxidant capacity of colon in patients with chronic ulcerative colitis. Dig Dis Sci 2000;45:1814-9.
98. Levy E, Rizwan Y, Thibault L, Lepage G, Brunet S, Bouthillier L, et al. Altered lipid proflle, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr 2000;71:807-15.
99. D'Odorico A, Bortolan S, Cardin R, D'Inca R, Martines D, Ferronato A, et al. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol 2001;36:1289-94.
100. Tuzun A, Erdil A, Inal V, Aydin A, Baʇci S, Yeşilova Z, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. Clin Biochem 2002;35:569-72.
101. Ciorba MA. Kynurenine pathway metabolites: Relevant to vitamin B-6 deficiency and beyond. Am J Clin Nutr 2013;98:863-4.
102. Clarke G, Fitzgerald P, Cryan JF, Cassidy EM, Quigley EM, Dinan TG. Tryptophan degradation in irritable bowel syndrome: Evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol 2009;9:6.
103. Sampietro GM, Cristaldi M, Cervato G, Maconi G, Danelli P, Cervellione R, et al. Oxidative stress, vitamin A and vitamin E behaviour in patients submitted to conservative surgery for complicated Crohn's disease. Dig Liver Dis 2010;34:696-701.
104. Barbosa DS, Cecchini R, El Kadri MZ, Rodríguez MA, Burini RC, Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemented with flsh oil omega-3 fatty acids. Nutrition 2003;19:837-42.
105. Rana SV, Sharma S, Prasad KK, Sinha SK, Singh K. Role of oxidative stress and antioxidant defence in ulcerative colitis patients from north India. Indian J Med Res 2014;139:568-71.
106. Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology 2003;125:58-69.
107. Hatoum OA, Binion DG, Miura H, Telford G, Otterson MF, Gutterman DD. Role of hydrogen peroxide in ACh-induced dilation of human submucosal intestinal microvessels. Am J Physiol Heart Circ Physiol 2005;288:H48-54.
108. Binion DG, Rafiee P. Is Inflammatory bowel disease a vascular disease? Targeting angiogenesis improves chronic inflammation in inflammatory bowel disease. Gastroenterology 2009;136:400-3.
109. Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: Semi-quantiflcation, localization, and association with mucosal antioxidants. J Pathol 2003;201:28-36.
110. Zelko IN, Mariani TJ, Folz RJ. Superoxide dismutase multigene family: A comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 2002;33:337-49.
111. Wirtz S, Neurath MF. Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007;59:1073-83.
112. Hoffmann JC, Pawlowski NN, Kühl AA, Höhne W, Zeitz M. Animal models of inflammatory bowel disease: An overview. Pathobiology 2002-2003;70:121-30.
113. Ardite E, Sans M, Panés J, Romero FJ, Piqué JM, Fernández-Checa JC. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab Invest 2000;80:735-44.
114. Nieto N, Torres MI, Fernández MI, Girón MD, Riós A, Suárez MD, et al. Experimental ulcerative colitis impairs antioxidant defense system in rat intestine. Dig Dis Sci 2000;45:1820-7.
115. Triantafillidis JK, Douvi G, Agrogiannis G, Patsouris E, Gikas A, Papalois AE. Effect of mesalamine and prednisolone on TNBS experimental colitis, following various doses of orally administered iron. Biomed Res Int 2014;2014:648535.
116. Tham DM, Whitin JC, Cohen HJ. Increased expression of extracellular glutathione peroxidase in mice with dextran sodium sulfate-induced experimental colitis. Pediatr Res 2002;51:641-6.
117. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003;94:965-73.
118. Ghazanfari G, Minaie B, Yasa N, Nakhai LA, Mohammadirad A, Nikfar S, et al. Biochemical and histopathological evidences for beneflcial effects of Satureja Khuzestanica Jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol Mech Methods 2007;16:365-72.
119. Ghafari H, Yasa N, Mohammadirad A, Dehghan G, Zamani MJ, Nikfar S, et al. Protection by Ziziphora clinopoides of acetic acid-induced toxic bowel inflammation through reduction of cellular lipid peroxidation and myeloperoxidase activity. Hum Exp Toxicol 2006;25:325-32.
120. Ding X, Hiraku Y, Ma N, Kato T, Saito K, Nagahama M, et al. Inducible nitric oxide synthase-dependent DNA damage in mouse model of inflammatory bowel disease. Cancer Sci 2005;96:157-63.
121. Jiang XL, Cui HF. A new chronic ulcerative colitis model produced by combined methods in rats. World J Gastroenterol 2000;6:742-6.
122. Mizoguchi E. Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. Gastroenterology 2006;130:398-411.
123. Papanikolaou IS, Psilopoulos DI, Liatsos C, Lazaris AC, Petraki K, Mavrogiannis C. Salmonella colitis or inflammatory bowel disease? A case demonstrating overlapping of clinical, endoscopic and pathologic features. Annual of Gastroenterology 2001;14:65-9.
124. Jensen SR, Fink LN, Nielsen OH, Brynskov J, Brix S. Ex vivo intestinal adhesion of Escherichia coli LF82 in Crohn's disease. Microb Pathog 2011;51:426-31.
125. Low D, Tran HT, Lee IA, Dreux N, Kamba A, Reinecker HC, et al. Chitin-binding domains of Escherichia coli chiA mediates interactions with intestinal epithelial cells in mice with colitis. Gastroenterology 2013;145:602-12.e9.
126. Nagatani K, Wang S, Llado V, Lau CW, Li Z, Mizoguchi A, et al. Chitin microparticles for the control of intestinal inflammation. Inflamm Bowel Dis 2013;18:1698-710.
127. Miles AM, Grisham MB. Antioxidant properties of aminosalicylates. Methods Enzymol 1994;234:555-72.
128. Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress: A randomized controlled trial. Am J Gastroenterol 2003;98:348-53.
129. Trebble TM, Arden NK, Wootton SA, Calder PC, Mullee MA, Fine DR, et al. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr 2004;80:1137-44.
130. Trebble TM, Stroud MA, Wootton SA, Calder PC, Fine DR, Mullee MA, et al. High-dose flsh oil and antioxidants in Crohn's disease and the response of bone turnover: A randomised controlled trial. Br J Nutr 2005;94:253-61.
131. Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel MG, Stockbrügger RW, et al. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: Effects on antioxidant status and fatty acid proflle. Inflamm Bowel Dis 2000;6:77-84.
132. Seidner DL, Lashner BA, Brzezinski A, Banks PL, Goldblum J, Fiocchi C, et al. An oral supplement enriched with flsh oil, soluble flber, and antioxidants for corticosteroid sparing in ulcerative colitis: A randomized, controlled trial. Clin Gastroenterol Hepatol 2004;3:358-69.
133. Oz HS, Chen TS, McClain CJ, de Villiers WJ. Antioxidants as novel therapy in a murine model of colitis. J Nutr Biochem 2005;16:297-304.
134. Abboud PA, Hake PW, Burroughs TJ, Odoms K, O'Connor M, Mangeshkar P, et al. Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol 2008;579:411-7.
135. Ran ZH, Chen C, Xiao SD. Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid. Biomed Pharmacother 2008;62:189-96.
136. Brückner M, Westphal S, Domschke W, Kucharzik T, Lügering A. Green tea polyphenol epigallocatechin-3-gallate shows therapeutic antioxidative effects in a murine model of colitis. J Crohns Colitis 2012;6:226-35.
137. Hagar HH, Medany A, El Eter E, Araf M. Ameliorative effect of pyrrolidinedithiocarbamate on acetic acid-induced colitis in rats. Eur J Pharmacol 2007;554:69-77.
138. Wang X, Zhao L, Han T, Chen S, Wang J. Protective effects of 2,3,5,4'-tetrahydroxystilbene-2-O-beta-d-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice. Eur J Pharmacol 2008;578:339-48.
139. Zhao ZJ, Xiang JY, Liu L, Huang XL, Gan HT. Parthenolide, an inhibitor of the nuclear factor-kB pathway, ameliorates dextran sulfate sodium-induced colitis in mice. Int Immunopharmacol 2012;12:169-74.
140. Funakoshi T, Yamashita K, Ichikawa N, Fukai M, Suzuki T, Gotoa R, et al. A novel NF-kB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. J Crohns Colitis 2012;6:215-25.
141. Dashdorj A, Jyothi KR, Lim S, Jo A, Nguyen MN, Ha J, et al. Mitochondria-targeted antioxidant MitoQ ameliorates experimental mouse colitis by suppressing NLRP3 inflammasome-mediated inflammatory cytokines. BMC Med 2013;11:178.
142. Koppikar SJ, Jagtap SD, Devarshi PP, Jangle NM, Awad VB, Wele AA, et al. Triphala, an Ayurvedic formulation improves the antioxidant status on TNBS induced IBD in rats. Eur J Integr Med 2014;6:646-56.
143. Ringel Y, Quigley EM, Lin HC. Using probiotics in gastrointestinal disorders. Am J Gastroenterol Suppl 2012;1:34-40.
144. Biasi F, Astegiano M, Maina M, Leonarduzzi G, Poli G. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease. Curr Med Chem 2014;18:4851-65.
145. Shapiro H, Singer P, Halpern Z, Bruck R. Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut 2007;56:426-35.
146. Romier B, Schneider YJ, Larondelle Y, During A. Dietary polyphenols can modulate the intestinal inflammatory response. Nutr Rev 2007;67:363-78.
147. Mueller D, Triebel S, Rudakovski O, Richling E. Influence of triterpenoids present in apple peel on inflammatory gene expression associated with inflammatory bowel disease (IBD). Food Chem 2013;139:339-46.
148. Alhouayek M, Muccioli GG. The endocannabinoid system in inflammatory bowel diseases: From pathophysiology to therapeutic opportunity. Trends Mol Med 2012;18:615-25.
149. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 2013;85:1306-16.